title: [Androgen deprivation therapy for prostate cancer: a follow-up study of the patients' survival time].
abstract: OBJECTIVE
  To explore the long-term survival and prognosis of prostate cancer patients after treated by androgen deprivation therapy.
  
  
  METHODS
  We conducted a follow-up study of 124 patients with prostate cancer treated by androgen deprivation therapy, and compared the survival times of the patients with different pathological grades and clinical characteristics using Kaplan-Meiers survival curves.
  
  
  RESULTS
  The mean survival time of the 124 patients after androgen deprivation therapy was 5. 912 years, with the median survival time of 7.81 years. The patients with bone metastases showed a shorter survival time than those with non-bone metastasis (P = 0.04). Pathological grades and PSA levels were not prognostic factors. No significant differences were found in the mean survival time between those died of prostate cancer (n = 35) and those from other factors (n = 23) (P = 0.50).
  
  
  CONCLUSIONS
  Bone metastasis is an important prognostic factor in advanced prostate cancer following androgen deprivation therapy, which is more significantly correlated with the survival time of the patients than tumor grades and clinical classification.
authors.affiliation: Department of Urology, Geriatric Hospital of Jiangsu Province, Nanjing, Jiangsu 210024, China. zsg2808@sina.com.cn
authors.forename: Shi-Ge
authors.initials: SG
authors.lastname: Zhang
authors.affiliation: Department of Urology, Geriatric Hospital of Jiangsu Province, Nanjing, Jiangsu 210024, China.
authors.forename: Jiu-Lin
authors.initials: JL
authors.lastname: Wang
authors.affiliation: Department of Urology, Geriatric Hospital of Jiangsu Province, Nanjing, Jiangsu 210024, China.
authors.forename: Ye
authors.initials: Y
authors.lastname: Wu
authors.affiliation: Department of Urology, Geriatric Hospital of Jiangsu Province, Nanjing, Jiangsu 210024, China.
authors.forename: Ning
authors.initials: N
authors.lastname: Shao
authors.affiliation: Department of Urology, Geriatric Hospital of Jiangsu Province, Nanjing, Jiangsu 210024, China.
authors.forename: Di
authors.initials: D
authors.lastname: Qiao
authors.affiliation: Department of Urology, Geriatric Hospital of Jiangsu Province, Nanjing, Jiangsu 210024, China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Ding
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000401:mortality* / Q000628:therapy*
chemical_list: D000726:Androgen Antagonists